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Abstract 
Issues: Methadone, a pharmacological agent used to treat heroin dependence is relatively safe, 
but may cause cardiac arrhythmias in the concurrent presence of other risk factors. Approach 
and key findings: This case report highlights the risk of Torsade de Pointes, a life threatening 
cardiac arrhythmia, in a heroin dependent patient receiving methadone substitution therapy 
who was prescribed itraconazole for vaginal thrush. The patient presented to the accident and 
emergency department for chest discomfort and an episode of syncope following two doses of 
itraconazole 200mg. ECG monitoring at the accident and emergency department showed 
prolonged rate-corrected QT interval leading to Torsade de Pointes. The patient was admitted 
for cardiac monitoring and ECG returned to normal upon discontinuation of methadone. 
Implication: This cardiac arrhythmia was most likely due to drug interaction between 
methadone and itraconazole because the patient presented with no other risk factors. 
Conclusion: Given the benefits of methadone as a substitution treatment for heroin dependent 
individuals, the association between methadone and cardiac arrhythmias is of great concern. 
Physicians treating heroin dependent patients on methadone substitution therapy should, 
therefore, be cautious of the potential risk of drug interactions which may lead to fatal cardiac 
arrhythmias.  
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Introduction 
 
Methadone, approved by the FDA in 1947, has only been introduced as a treatment 
option for heroin dependent individuals in Malaysia in the past 3 years [1]. Methadone 
has been widely studied and prescribed worldwide, and has proven to be an established 
and effective pharmacological agent to treat heroin dependent patients [2, 3]. However, 
methadone induced prolonged QTc and Torsade de Pointes have been reported in the 
literature [4, 5, 6]. More recently, studies of drug interactions involving methadone which 
resulted in cardiac arrhythmias have also emerged [7, 8], largely among the western 
population.  
 
This report highlights the first known reported case in Malaysia of a female heroin 
dependent individual on methadone substitution therapy who developed prolonged rate-
corrected QT interval (QTc) and torsade de pointes following concomitant administration 
of itraconazole. 
 
Case description 
 
A 44-year-old Malay female presented to the accident and emergency department 
following an episode of chest discomfort and syncope. She had been having itchy whitish 
curd-like vaginal discharge for 2 weeks and had visited her general practitioner who had 
prescribed two doses of oral itraconazole 200mg one day earlier. A review of her past 
medical history showed that she was a previous intravenous heroin user who was 
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attending a community methadone substitution programme for the past 9 months. She 
was on syrup methadone 120 mg daily and claimed to be responding well to the 
community opiate substitution programme as she was heroin-free for the last 4 months. 
She denied any side effect or medical problems since taking methadone. She was not 
known to have cardiac, respiratory, hepatic or neurological disease. She was divorced 
with no children and works as a security guard. She is sexually active, stays in a rented 
apartment with her partner and smokes 14 cigarettes per day. 
 
Physical examination revealed a conscious but lethargic looking female with normal vital 
signs and with no cardiovascular, respiratory or neurological abnormalities. Continuous 
electrocardiogram (ECG) monitoring at the emergency department showed sinus rhythm 
with a QTc interval of 520 ms (milliseconds) leading to torsade de pointes, but resolved 
spontaneously. Blood investigations revealed normal blood count and serum electrolytes, 
normal liver function, normal renal function and normal cardiac enzymes. Unfortunately, 
no analysis of plasma for methadone concentration was done.  
 
She was admitted to the cardiac ward for monitoring, where her methadone was 
discontinued and changed to buprenorphine, and she was prescribed potassium and 
magnesium supplements. The patient’s cardiovascular status remained stable and 
subsequent ECG monitoring after methadone cessation were normal. The patient was 
discharged on the third day and a follow-up at the cardiology clinic 3 months later 
revealed no further cardiac symptoms and her ECG was normal. 
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Discussion 
 
This case report highlights the risk of cardiac arrhythmias, in particular QTc interval 
prolongation leading to torsade de pointes, due to drug interaction in a Malay female 
patient receiving methadone substitution therapy. 
 
Torsade de Pointes, a life-threatening ventricular tachycardia has unique ECG 
characteristics of twisting of the QRS complex around the isoelectric line and associated 
with prolonged QTc interval, which may degenerate into sustained ventricular 
tachycardia and ventricular fibrillation [9]. Among the known predisposing factors for 
acquired torsade de pointes include an underlying cardiac or liver abnormality, electrolyte 
imbalance (hypokalaemia and hypomagnesaemia) and drugs (methadone, antihistamines, 
antipsychotics and some antibiotics) [9, 10]. Torsade de Pointes was also more often 
reported in females [11].  
 
Methadone induced cardiac arrhythmia is thought to be due to the blockade of cardiac K
+
 
channel. As a consequence, the QTc interval becomes prolonged and this may precipitate 
ventricular arrhythmias [11]. In the above patient, the normalization of the ECG 
following methadone cessation suggests that the torsade de pointes was most likely 
caused by methadone—a finding strengthened by the fact that there was an absence of 
other underlying factors such as structural heart disease, illicit drugs, other QTc 
prolonging drugs or hypokalemia.  The itraconazole merely acted as a potentiator that 
increased the serum methadone level and led to further Ikr blockade. Walker et al., also 
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report cases where the QTc interval returned to normal following discontinuation of 
methadone [7]. 
 
Methadone is metabolized in the liver and these processes mainly involve the cytochrome 
enzymes CYP1A2, CYP2D6 and CYP3A4 [7]. The combination of methadone and a 
CYP3A4 inhibitor increases the risk of adverse effects [7, 12]. Some of these drugs 
include the azole antimycotics (ketoconazole and itraconazole), antibiotics (e.g., 
fluoroquinolones and macrolides), calcium channel antagonists (diltiazem and verapamil) 
and grapefruit juice [9, 13]. The use of a CYP3A4 inhibitor can decrease drug 
metabolism both during the first pass and the elimination phases. The decrease in drug 
elimination may enhance its therapeutic and also its toxic effects.  
 
The proarrythmic capacity of methadone is reported to be mainly dose dependent, where 
QTc prolongation and torsade de pointes was more often reported in patients on high 
dose methadone—mean daily dosage  397 mg. [14] However, cases of prolonged QTc 
interval and torsade de pointes have also been reported over a wide range of dosages 
including doses that were recommended for addiction treatment [15]. In the above patient, 
ventricular arrhythmia developed on a lower dose of 120 mg daily.  
 
Methadone is relatively safe when prescribed within recommended doses and with full 
monitoring by health personnel and the small risk of torsade de pointes should not deter 
physicians from offering it as a treatment option to heroin dependent individuals. The risk 
of arrhythmia only arises with the concurrent presence of other risk factors such as 
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existing cardiac or liver disease and potential interaction between methadone and other 
drugs such as antimycotics and antibiotics. Extra caution is also warranted in situations 
that cause hypokalaemia such as diarrhoea or vomiting and use of diuretics.  Pre-
treatment electrocardiogram (ECG) screening is recommended in such cases [11, 15, 16]. 
More specific guidelines in the literature call for pre-treatment ECG to measure the QTc 
interval to be followed up by another within 30 days and annually thereafter.  Additional 
ECG is indicated if methadone doses exceed 100mg/day or if unexplained syncope/ 
seizures are present [11]. Patients on methadone should be educated to seek medical 
advice before ingesting other drugs and to seek medical treatment and assessment if they 
experience chest discomfort, palpitations or dizziness. In patients who experienced 
methadone induced arrhythmias, an alternative safer medication such as buprenorphine, 
which is a partial opioid agonist should be offered. Buprenorphine is a less potent Ikr 
blocker [17] and therefore has a better safety profile. The lower risk of QTc prolongation 
with buprenorphine is well supported by clinical studies [18, 19, 20]. 
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